Baidu
map

Neurology:CHANCE研究:双抗治疗轻型卒中/TIA获益主要在前2周

2017-05-18 佚名 中国循环杂志

近日,Neurology杂志发表了我国学者王拥军、王伊龙等开展的CHANCE研究的最新成果:轻型卒中或TIA患者早期采用阿司匹林+氯吡格雷双联抗血小板治疗的净获益可能在最初2周内,净获益主要是指新发缺血性卒中减少的益处超出血增加的风险。研究数据显示,氯吡格雷-阿司匹林双联抗血小板治疗在前2周可以减少新发缺血性卒中风险,但在第3周新发缺血性卒中事件在数值上有所增加。而在出血方面,氯吡格雷-阿司匹林双

近日,Neurology杂志发表了我国学者王拥军、王伊龙等开展的CHANCE研究的最新成果:轻型卒中或TIA患者早期采用阿司匹林+氯吡格雷双联抗血小板治疗的净获益可能在最初2周内,净获益主要是指新发缺血性卒中减少的益处超出血增加的风险。

研究数据显示,氯吡格雷-阿司匹林双联抗血小板治疗在前2周可以减少新发缺血性卒中风险,但在第3周新发缺血性卒中事件在数值上有所增加。

而在出血方面,氯吡格雷-阿司匹林双联抗血小板治疗在最初的4周任意出血风险高于阿司匹林单抗治疗。

在氯吡格雷-阿司匹林双联抗血小板治疗组,最初1月内共有4例中度到中度出血,1例发生在第1周,2例在第2周,1例在第3周。阿司匹林组最初1月无中重度出血事件。

进一步分析显示,氯吡格雷+阿司匹林双联抗血小板治疗减少的新发缺血性卒中事件和增加的出血事件数的差别随着双抗治疗时间的延长逐渐变小,曲线在第10天的时候交叉。

关于临床净获益的敏感性分析显示,如果出血相较于新发缺血性卒中权重为0.8或者更低,则双抗治疗在前2周具有正向的净获益。

目前中国与美国AHA/ASA指南关于急性缺血性卒中早期管理的指南中,均推荐轻型卒中及TIA应用氯吡格雷+阿司匹林治疗21天。

Neurology杂志对于文章的发表也给予了高度的重视和赞赏。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-21 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-06-07 I come

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-06-03 I come

    精准医学的证据

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-20 chendoc247
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-20 chendoc247
  7. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 1e1b8538m79(暂无匿称)

    这个是个不错的研究观点

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1747668, encodeId=fa3d1e47668bc, content=<a href='/topic/show?id=ed7d935940d' target=_blank style='color:#2F92EE;'>#轻型卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93594, encryptionId=ed7d935940d, topicName=轻型卒中)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=002835934077, createdName=tcm111hq, createdTime=Wed Aug 30 23:18:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999949, encodeId=b2f21999949d8, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 21 11:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207532, encodeId=d58f20e53276, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jun 07 06:48:50 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205846, encodeId=595520584698, content=精准医学的证据, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Sat Jun 03 07:01:22 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564268, encodeId=6ada156426884, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558259, encodeId=1c071558259ea, content=<a href='/topic/show?id=c99f45e9dc' target=_blank style='color:#2F92EE;'>#CHANCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4579, encryptionId=c99f45e9dc, topicName=CHANCE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daed14955633, createdName=chendoc247, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487223, encodeId=a3c1148e2235a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429115, encodeId=13d2142911547, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37464, encryptionId=168a3e464ad, topicName=双抗治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f6a4173831, createdName=zhangbaojun, createdTime=Sat May 20 08:18:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200039, encodeId=e77f200039b3, content=这个是个不错的研究观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 19 16:11:33 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199929, encodeId=24f31999290d, content=那就是前两周给予双抗,之后就阿司匹林单抗就可以了, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epcEuqMhg8HWu4Gq5Q6dXbZoOZUHP9R4CPzic54riasPo87A9c46h3NIMWiaoiatjoEbw32hEA86rD4zg/132, createdBy=37942047541, createdName=玲儿0000, createdTime=Fri May 19 09:31:30 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 玲儿0000

    那就是前两周给予双抗,之后就阿司匹林单抗就可以了

    0

相关资讯

美指南采纳中国双重抗血小板方案

国际脑血管病领域最权威、影响力最大的指南——美国心脏协会/美国卒中协会(AHA/ASA)日前发布的新版《缺血性卒中及短暂性脑缺血发作患者卒中预防指南》中,首次纳入中国CHANCE研究成果“双重抗血小板治疗方案”,并且在临床给出了单独作为B级证据的推荐意见。 中国CHANCE研究(Clopidogrel in High-risk patients with Acute Non-disabling

Baidu
map
Baidu
map
Baidu
map